Essential Patient and Caregiver Education for Tarlatamab Treatment Success

EP: 1.ES-SCLC vs LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis

EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC

EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management

EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC

EP: 5.Institutional Implementation: Setting Up Tarlatamab Administration

EP: 6.Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation

EP: 7.Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab

EP: 8.Tarlatamab Administration and Postinfusion Monitoring

Now Viewing

EP: 9.Essential Patient and Caregiver Education for Tarlatamab Treatment Success

EP: 10.Neurological Toxicity Recognition: ICANS Assessment and Management

EP: 11.CRS Recognition and Intervention: Timing and Clinical Features

EP: 12.Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue

EP: 13.Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies

EP: 14.Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS

EP: 15.Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management

EP: 16.Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum

EP: 17.Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit

Summary for Physicians:

Education Materials/Resources Provided:

• Treatment overview:
• Detailed explanation of tarlatamab, its purpose, and expected benefits.

• Overview of the administration process and frequency of infusions.
• Potential adverse effects:
• Information on common adverse effects (eg, fever, fatigue) and serious adverse events (eg, cytokine release syndrome).

• Signs and symptoms to watch for, and when to seek immediate medical attention.
• Monitoring requirements:
• Postinfusion monitoring expectations (eg, observation for 1-2 hours after infusion).

• Follow-up appointments and any additional monitoring required.
• Support resources:
• Access to 24/7 nursing support for urgent questions or concerns.

• Contact information for the pharmacy and oncology team.

Challenges:

Ensuring patients and caregivers fully understand the information and know how to recognize early signs of adverse reactions.